paroxetine + sulpiride

Paroxetine + sulpiride is a combination of two pharmaceutical agents used together primarily in psychiatric indications. Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin levels by inhibiting the sodium-dependent serotonin transporter, leading to antidepressant and anxiolytic effects[4]. Sulpiride is a substituted benzamide antipsychotic that acts as a selective dopamine D2 and D3 receptor antagonist, modulating dopaminergic neurotransmission[5]. The combination has been studied for its potential to accelerate antidepressant response in major depressive disorder compared to paroxetine monotherapy, with evidence suggesting faster onset of action and superior early improvement in depressive symptoms[1][3][6][7]. Both drugs are small molecules administered orally. The combination may also be considered for other neuropsychiatric or pain-related conditions where modulation of both serotonergic and dopaminergic pathways could be beneficial.